Previous 10 | Next 10 |
At the conclusion of the 2021 Russell indexes annual reconstitution, following notable healthcare stocks will join the Russell Microcap Index, effective June 28 after the U.S. market opens.Asensus Surgical (ASXC), Organovo Holdings (ONVO), Senseonics Holdings (SENS), Clovis Onc...
Gainers: Energy Focus (EFOI) +61%.SemiLEDs (LEDS) +44%.GTT Communications (GTT) +40%.The InterGroup (INTG) +30%.Community Bankers Trust (ESXB) +30%.Workhorse Group (WKHS) +27%.Kindred Biosciences (KIN) +27%.Conn's (CONN) +26%.Tellurian (TELL) +22%.MoSys (MOSY) +21%.Losers: Tian...
Gainers: Ra Medical Systems (RMED) +25%, Sundial Growers (SNDL) +24%, Kindred Biosciences (KIN) +14%, Lannett (LCI) +11%, IGM Biosciences IGMS +11%.Losers: PetMed Express (PETS) -25%, SELLAS Life Sciences (SLS) -15%, Replimune REPL ...
SELLAS Life Sciences (SLS) has issued an update on “at-the-market” offering program entered with Cantor Fitzgerald on April 16.Per the agreement, the company was expected to offer or sell shares of its common stock targeting gross sale proceeds of up to $50.0M.Since the da...
The USPTO has issued a Notice of Allowance to Sellas Life Sciences Group (SLS) for a patent application covering the use of galinpepimut-S ((GPS)), the Wilms Tumor-1 (WT1)-targeting peptide immunotherapeutic, in combination with checkpoint inhibitor therapies for treatment of WT1-expressing c...
NEW YORK, May 27, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today announced that the ...
SELLAS Life Sciences (SLS): Q1 GAAP EPS of -$0.16 beats by $0.02.Revenue of $5.7MCash and cash equivalents totaled ~$28M.Press Release For further details see: SELLAS Life Sciences EPS beats by $0.02
Received $1.0 Million Milestone Payment and Recognized $5.7 Million of License Revenue Under Exclusive License Agreement with 3D Medicines for Development and Commercialization of Galinpepimut-S (GPS) in Greater China National Ethics Committee Approval for GPS Phase 3 REGAL Stud...
NEW YORK, May 11, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today announced that ...
Gainers: Scienjoy (SJ) +48%.Second Sight Medical Products (EYES) +36%.Greenwich LifeSciences (GLSI) +32%.Brooklyn ImmunoTherapeutics (BTX) +31%.Romeo Power (RMO) +28%.Target Hospitality (TH) +27%.BBQ Holdings (BBQ) +27%.SELLAS Life Sciences (SLS) +22%.GT Biopharma (GT...
News, Short Squeeze, Breakout and More Instantly...
SELLAS Life Sciences Group Inc. Company Name:
SLS Stock Symbol:
NASDAQ Market:
SELLAS Life Sciences Group Inc. Website:
2024-07-19 10:10:00 ET July 19, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the Biotech, Cleantech Sectors. The newest biotech companies are involved in blood disorder treat...
- Acute Myeloid Leukemia (AML) is the Second Most Common Hematological Malignancy in Children Often Associated with Poorer Prognosis Compared to Other Pediatric Cancers – - This Recognition Marks SELLAS’ Second RPDD Following the Designation for ALL Received Last Month - -...
NEW YORK, July 08, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today ...